Ważyńska MA., Butera R., Requesens M., Plat A., Zarganes-Tzitzikas T., Neochoritis CG., Plewka J., Skalniak L., Kocik-Krol J., Musielak B., Magiera-Mularz K., Rodriguez I., Blok SN., de Bruyn M., Nijman HW., Elsinga PH., Holak TA., Dömling A.

In search of a potent small molecular PD-L1 inhibitor, we designed and synthesized a compound based on a 2-hydroxy-4-phenylthiophene-3-carbonitrile moiety. Ligand's performance was tested in vitro and compared side-by-side with a known PD-L1 antagonist with a proven bioactivity BMS1166. Subsequently, we modified both compounds to allow 18F labeling that could be used for PET imaging. Radiolabeling, which is used in drug development and diagnosis, was applied to investigate the properties of those ligands and test them against tissue sections with diverse expression levels of PD-L1. We confirmed biological activity toward hPD-L1 for this inhibitor, comparable with BMS1166, while holding enhanced pharmacological properties.

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors.

Ważyńska MA., Butera R., Requesens M., Plat A., Zarganes-Tzitzikas T., Neochoritis CG., Plewka J., Skalniak L., Kocik-Krol J., Musielak B., Magiera-Mularz K., Rodriguez I., Blok SN., de Bruyn M., Nijman HW., Elsinga PH., Holak TA., Dömling A.

DOI

Type

Journal

Publication Date

Volume

Pages

Addresses

Keywords